Trial Profile
An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide
- Indications Ovarian cancer
- Focus Pharmacodynamics
- Sponsors Endocyte
- 06 Feb 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 30 Apr 2018 to 1 Aug 2018.
- 30 Mar 2018 Planned End Date changed from 1 Jun 2018 to 30 Apr 2018.